Post-market plans, formerly called regulatory agreements, will be piloted
This article was originally published in The Gold Sheet
FDA is planning two pilots of post-market plans, the agency's new name for regulatory agreements, which would allow for extra flexibility, for example to make changes without filing supplements. The first pilot will be for companies that are submitting quality-by-design filings, Office of Pharmaceutical Science Director Helen Winkle told the PDA/FDA meeting in Washington on Sept. 24. The second pilot will be for filings that did not use the quality-by-design approach, either because they are for legacy products or for new products that don't need lots of QbD information or risk assessment work, but still could use some regulatory flexibility
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.